Palifermin (marketed as Kepivance)
FDA approves Palifermin, a modified version of a naturally occurring human
protein called keratinocyte growth factor (KGF) that is manufactured
in a laboratory. Palifermin is used to reduce the chances of developing severe
mucositis (injury to the cells lining the mouth) and to shorten the
time with severe mucositis in patients with cancer who receive high
doses of chemotherapy and radiation therapy followed by stem cell
rescue.
PDF requires the free Adobe
Acrobat Reader
Back
to Top
Back to Drug Info
Date created: December 15, 2004,
updated January 18, 2007 |